Upgrade to SI Premium - Free Trial

Larimar Therapeutics (LRMR)

3.29 +0.09 (2.81%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight May 27, 2026 1:09 AM - StreetInsider Form 4 Larimar Therapeutics, For: May 19 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. May 20, 2026 8:03 PM - SEC Filing Form 4 Larimar Therapeutics, For: May 19 Filed by: LEFF JONATHAN S May 20, 2026 6:04 PM - SEC Filing Form 4 Larimar Therapeutics, For: May 19 Filed by: SHERMAN JEFFREY W May 20, 2026 4:31 PM - SEC Filing Form 4 Larimar Therapeutics, For: May 19 Filed by: Truitt Joseph May 20, 2026 4:28 PM - SEC Filing Form 4 Larimar Therapeutics, For: May 19 Filed by: THOMAS FRANK E May 20, 2026 4:25 PM - SEC Filing Form 4 Larimar Therapeutics, For: May 19 Filed by: Hamilton Thomas Edward May 20, 2026 4:22 PM - SEC Filing Form 8-K Larimar Therapeutics, For: May 19 May 19, 2026 4:28 PM - SEC Filing Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens May 15, 2026 5:03 AM - StreetInsider Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: Blue Owl Capital Holdings LP May 14, 2026 4:24 PM - SEC Filing Form 10-Q Larimar Therapeutics, For: Mar 31 May 14, 2026 4:19 PM - SEC Filing Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c May 14, 2026 7:34 AM - StreetInsider Form 8-K Larimar Therapeutics, For: May 14 May 14, 2026 7:03 AM - SEC Filing Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update May 14, 2026 7:01 AM - Globe NewsWire Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC April 30, 2026 6:17 PM - SEC Filing Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia April 30, 2026 4:05 PM - Globe NewsWire Form ARS Larimar Therapeutics, For: Dec 31 April 20, 2026 4:09 PM - SEC Filing Form DEF 14A Larimar Therapeutics, For: Apr 17 April 20, 2026 4:07 PM - SEC Filing Form PRE 14A Larimar Therapeutics, For: May 19 April 10, 2026 4:10 PM - SEC Filing Form S-8 Larimar Therapeutics, March 19, 2026 5:04 PM - SEC Filing Form 10-K Larimar Therapeutics, For: Dec 31 March 19, 2026 3:42 PM - SEC Filing William Blair on Larimar Therapeutics (LRMR): not without risk but favorable risk/reward March 19, 2026 2:38 PM - StreetInsider Guggenheim on Larimar (LRMR): 'With multiple near-term catalysts on the horizon, we see substantial upside potential' March 19, 2026 12:57 PM - StreetInsider Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 24c March 19, 2026 7:57 AM - StreetInsider Form 8-K Larimar Therapeutics, For: Mar 19 March 19, 2026 7:05 AM - SEC Filing Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results March 19, 2026 7:02 AM - Globe NewsWire Full Article List